Das könnte Sie auch interessieren:

Terence Hill wird 80! "Ich habe nur Deutsch gesprochen, bis ich sechs Jahre war ..." - kabel eins spricht zu seinem Jubiläum exklusiv mit dem Italo-Star

Unterföhring (ots) - 24. März 2019. Er ist Kult, er ist cool, und am Freitag wird er 80: Terence Hill ist ...

Erstes SUPER COMMUNICATION LAND by news aktuell begeistert die PR- und Marketing-Branche

Hamburg (ots) - Gestern fand zum ersten Mal das SUPER COMMUNICATION LAND von news aktuell statt. In THE BOX, ...

ÖKO-TEST überprüft für Gratis-Test erstmals 400 Produkte / Unser Testurteil zu allen wichtigen Zahncremes jetzt exklusiv online

Frankfurt am Main (ots) - Fünf Zahnpastatuben verbraucht jeder von uns durchschnittlich im Jahr. Stolze 734 ...

14.02.2019 – 09:00

Debiopharm International SA

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion
  • Bild-Infos
  • Download

Lausanne, Switzerland (ots)

Patients will be recruited in North America, Europe, South America and the Asia Pacific region.

Debiopharm International SA (Debiopharm - www.debiopharm.com/debiopharm-international/), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the start of FUZE, a clinical phase II study to evaluate Debio 1347 for the treatment of solid tumors harboring an FGFR fusion (NCT03834220).

The presence of a specific alteration of the fibroblast growth factor receptor (FGFR) genes - called a fusion - deregulates FGFR signaling pathways and drives cancer growth. Debio 1347 is a potent selective inhibitor of FGFRs.

This study will enroll patients with advanced or metastatic tumors whose cells show specific FGFR gene alterations, namely FGFR1, FGFR2 or FGFR3 gene fusions. The purpose of the trial is to demonstrate that Debio 1347 can bring clinical benefit to patients with tumors harboring an FGFR fusion.

"Historically, cancer therapies have been approved for use on the basis of the tumor's location and stage of cancer. The FUZE clinical trial has been designed on the basis of a specific tumor's genetic alteration, rather than its location. This tissue-agnostic approach could therefore benefit cancer patients with a rare genetic alteration, such as an FGFR fusion, irrespective of tumor type. We are committed to using innovative treatment approach guided by advanced technologies to meet unmet needs with the intent to improve outcomes and quality of life for cancer patients". - Claudio Zanna, Group Medical Director at Debiopharm International SA

About Debio 1347

Debio 1347 is an investigational novel orally available small molecule highly selective FGFR 1, 2, 3 ATP competitive inhibitor. Results from the phase 1 clinical trial showed that patients with solid tumors with activating alterations in FGFR may benefit from treatment with Debio 1347. Debio 1347 is expected to become a tailored treatment which will be developed with a companion diagnostic.

For more information: https://patients.debiopharm.com/genetic-alterations/

About Debiopharm International SA

Part of Debiopharm Group(TM), Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please visit www.debiopharm.com/debiopharm-international/

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews


Debiopharm International SA
Christelle von Büren
Communication Coordinator
Tel: +41 (0)21 321 01 11

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell

Alle Meldungen
Abonnieren Sie alle Meldungen von Debiopharm International SA
  • Druckversion
  • PDF-Version

Orte in dieser Meldung

Themen in dieser Meldung

Weitere Meldungen: Debiopharm International SA